Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Guided Therapeutics (GTHP) over the last 15 years, with Q3 2025 value amounting to $22000.0.

  • Guided Therapeutics' Share-based Compensation fell 6986.3% to $22000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $339000.0, marking a year-over-year increase of 32911.39%. This contributed to the annual value of $120000.0 for FY2024, which is 9335.55% down from last year.
  • As of Q3 2025, Guided Therapeutics' Share-based Compensation stood at $22000.0, which was down 6986.3% from $329981.0 recorded in Q2 2025.
  • In the past 5 years, Guided Therapeutics' Share-based Compensation registered a high of $1.1 million during Q2 2023, and its lowest value of -$54000.0 during Q4 2023.
  • For the 5-year period, Guided Therapeutics' Share-based Compensation averaged around $159052.6, with its median value being $56000.0 (2021).
  • Examining YoY changes over the last 5 years, Guided Therapeutics' Share-based Compensation showed a top increase of 244318.18% in 2023 and a maximum decrease of 11406.25% in 2023.
  • Guided Therapeutics' Share-based Compensation (Quarter) stood at $50000.0 in 2021, then skyrocketed by 668.0% to $384000.0 in 2022, then crashed by 114.06% to -$54000.0 in 2023, then surged by 75.93% to -$13000.0 in 2024, then soared by 269.23% to $22000.0 in 2025.
  • Its last three reported values are $22000.0 in Q3 2025, $329981.0 for Q2 2025, and $19.0 during Q1 2025.